- Lexaria Bioscience Corp. is the only company worldwide with patents issued for oral delivery of all cannabinoids
- Its proprietary technology bests traditional methods such as inhalation in several key ways
- The company continues to enhance its intellectual property portfolio as it pursues patents around the world
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a food biosciences company, has developed a proprietary technology that has revolutionized the way cannabidiol (CBD) and other non-psychoactive cannabinoids are delivered into the bloodstream.
Lexaria, the only company worldwide with patents issued for oral delivery of all cannabinoids, has greatly improved the delivery of bioactive compounds. While cannabinoids typically enter the bloodstream in three main ways, each has its limitations. Inhalation is harmful to the lungs; sub-lingual (under the tongue) consumption carries a bitter taste unless copiously sweetened; and oral consumption is typically is very slow to act, often between one and three hours.
As a disruptor in the cannabis industry, Lexaria’s DehydraTECH drug delivery platform is changing the way cannabinoids enter the bloodstream through the gastrointestinal tract. Its proprietary technology promises multiple advantages in cannabinoid edibles. First, it masks the undesirable taste typically found in cannabinoid edibles, eliminating the need to add sweetening agents and enabling sugar-free options. Second, it increases the product’s absorption rate, with absorption occurring at two- to five-times higher rates than other edibles. Finally, it reduces the time of onset; effects of the product are felt within 15-20 minutes of consumption rather than the typical 60-120 minutes. In a March 2016 focus study, subjects ranked Lexaria’s formulation as the best tasting and most palatable option. They also found it to deliver the highest-quality THC experience overall.
Some of Lexaria’s featured products have included protein energy bars; CBD tablets; exotic teas delivering CBD in multiple flavors; coffee; and TurboCBD capsules, which are described as “high absorption, full spectrum hemp oil capsules aimed to increase focus and memory while also reducing stress and fatigue.”
While Lexaria’s groundbreaking technology has set a new quality standard for other companies to aspire to, the company also takes pride in its pursuance of a strong intellectual property portfolio. By the end of 2018, the company’s portfolio included 53 patent applications pending in over 40 countries worldwide, as well as 10 patents already granted. Anticipating new patent awards in 2019 both in the United States and across the world, Lexaria continues to make inroads into various industries through its research and development and key business relationships.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
